FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296003003> ?p ?o ?g. }

• W4296003003 endingPage "10587" @default.
• W4296003003 startingPage "10587" @default.
• W4296003003 abstract "Metabolic characteristics of kidney cancers have mainly been obtained from the most frequent clear cell renal cell carcinoma (CCRCC) studies. Moreover, the bioenergetic perturbances that affect metabolic adaptation possibilities of papillary renal cell carcinoma (PRCC) have not yet been detailed. Therefore, our study aimed to analyze the in situ metabolic features of PRCC vs. CCRCC tissues and compared the metabolic characteristics of PRCC, CCRCC, and normal tubular epithelial cell lines. The protein and mRNA expressions of the molecular elements in mammalian target of rapamycin (mTOR) and additional metabolic pathways were analyzed in human PRCC cases compared to CCRCC. The metabolic protein expression pattern, metabolite content, mTOR, and metabolic inhibitor sensitivity of renal carcinoma cell lines were also studied and compared with tubular epithelial cells, as normal control. We observed higher protein expressions of the alternative bioenergetic pathway elements, in correlation with the possible higher glutamine and acetate consumption in PRCC cells instead of higher glycolytic and mTOR activity in CCRCCs. Increased expression of certain metabolic pathway markers correlates with the detected differences in metabolite ratios, as well. The lower lactate/pyruvate, lactate/malate, and higher pyruvate/citrate intracellular metabolite ratios in PRCC compared to CCRCC cell lines suggest that ACHN (PRCC) have lower Warburg glycolytic capacity, less pronounced pyruvate to lactate producing activity and shifted OXPHOS phenotype. However, both studied renal carcinoma cell lines showed higher mTOR activity than tubular epithelial cells cultured in vitro, the metabolite ratio, the enzyme expression profiles, and the higher mitochondrial content also suggest increased importance of mitochondrial functions, including mitochondrial OXPHOS in PRCCs. Additionally, PRCC cells showed significant mTOR inhibitor sensitivity and the used metabolic inhibitors increased the effect of rapamycin in combined treatments. Our study revealed in situ metabolic differences in mTOR and metabolic protein expression patterns of human PRCC and CCRCC tissues as well as in cell lines. These underline the importance in the development of specific new treatment strategies, new mTOR inhibitors, and other anti-metabolic drug combinations in PRCC therapy." @default.
• W4296003003 created "2022-09-16" @default.
• W4296003003 creator A5004593235 @default.
• W4296003003 creator A5020826438 @default.
• W4296003003 creator A5026413228 @default.
• W4296003003 creator A5030444428 @default.
• W4296003003 creator A5051738563 @default.
• W4296003003 creator A5055379268 @default.
• W4296003003 creator A5057056068 @default.
• W4296003003 creator A5061632602 @default.
• W4296003003 creator A5071006573 @default.
• W4296003003 creator A5072754009 @default.
• W4296003003 creator A5079221711 @default.
• W4296003003 creator A5082284531 @default.
• W4296003003 date "2022-09-13" @default.
• W4296003003 modified "2023-10-18" @default.
• W4296003003 title "Metabolic Adaptation as Potential Target in Papillary Renal Cell Carcinomas Based on Their In Situ Metabolic Characteristics" @default.
• W4296003003 cites W1493127207 @default.
• W4296003003 cites W1576155197 @default.
• W4296003003 cites W1578932543 @default.
• W4296003003 cites W1772301402 @default.
• W4296003003 cites W1842974971 @default.
• W4296003003 cites W1972254548 @default.
• W4296003003 cites W2003921338 @default.
• W4296003003 cites W2014177895 @default.
• W4296003003 cites W2044515618 @default.
• W4296003003 cites W2097259163 @default.
• W4296003003 cites W2132117833 @default.
• W4296003003 cites W2141444851 @default.
• W4296003003 cites W2149441684 @default.
• W4296003003 cites W2160784270 @default.
• W4296003003 cites W2234115940 @default.
• W4296003003 cites W2234445408 @default.
• W4296003003 cites W2404698302 @default.
• W4296003003 cites W2516363685 @default.
• W4296003003 cites W2560197991 @default.
• W4296003003 cites W2565408756 @default.
• W4296003003 cites W2739389566 @default.
• W4296003003 cites W2764252414 @default.
• W4296003003 cites W2769631867 @default.
• W4296003003 cites W2771697100 @default.
• W4296003003 cites W2783405303 @default.
• W4296003003 cites W2787693514 @default.
• W4296003003 cites W2789557649 @default.
• W4296003003 cites W2794406366 @default.
• W4296003003 cites W2795319633 @default.
• W4296003003 cites W2806111894 @default.
• W4296003003 cites W2810450068 @default.
• W4296003003 cites W2884761694 @default.
• W4296003003 cites W2898144712 @default.
• W4296003003 cites W2914788991 @default.
• W4296003003 cites W2945220204 @default.
• W4296003003 cites W2953092095 @default.
• W4296003003 cites W2969782323 @default.
• W4296003003 cites W2971575751 @default.
• W4296003003 cites W2992324722 @default.
• W4296003003 cites W2996642684 @default.
• W4296003003 cites W2997046468 @default.
• W4296003003 cites W2999417355 @default.
• W4296003003 cites W3005216907 @default.
• W4296003003 cites W3015450697 @default.
• W4296003003 cites W3087381804 @default.
• W4296003003 cites W3134347112 @default.
• W4296003003 cites W3137990711 @default.
• W4296003003 cites W3158263555 @default.
• W4296003003 cites W4205583015 @default.
• W4296003003 cites W4205974265 @default.
• W4296003003 cites W4237816489 @default.
• W4296003003 doi "https://doi.org/10.3390/ijms231810587" @default.
• W4296003003 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36142502" @default.
• W4296003003 hasPublicationYear "2022" @default.
• W4296003003 type Work @default.
• W4296003003 citedByCount "1" @default.
• W4296003003 countsByYear W42960030032023 @default.
• W4296003003 crossrefType "journal-article" @default.
• W4296003003 hasAuthorship W4296003003A5004593235 @default.
• W4296003003 hasAuthorship W4296003003A5020826438 @default.
• W4296003003 hasAuthorship W4296003003A5026413228 @default.
• W4296003003 hasAuthorship W4296003003A5030444428 @default.
• W4296003003 hasAuthorship W4296003003A5051738563 @default.
• W4296003003 hasAuthorship W4296003003A5055379268 @default.
• W4296003003 hasAuthorship W4296003003A5057056068 @default.
• W4296003003 hasAuthorship W4296003003A5061632602 @default.
• W4296003003 hasAuthorship W4296003003A5071006573 @default.
• W4296003003 hasAuthorship W4296003003A5072754009 @default.
• W4296003003 hasAuthorship W4296003003A5079221711 @default.
• W4296003003 hasAuthorship W4296003003A5082284531 @default.
• W4296003003 hasBestOaLocation W42960030031 @default.
• W4296003003 hasConcept C109156525 @default.
• W4296003003 hasConcept C126322002 @default.
• W4296003003 hasConcept C134018914 @default.
• W4296003003 hasConcept C190283241 @default.
• W4296003003 hasConcept C20251656 @default.
• W4296003003 hasConcept C2776531350 @default.
• W4296003003 hasConcept C2777477808 @default.
• W4296003003 hasConcept C2779349466 @default.
• W4296003003 hasConcept C2780091579 @default.
• W4296003003 hasConcept C502942594 @default.

• next